SCHEMBL26213112

SCHEMBL26213112

[N-]=[N+]=NCC1CCN(CCNS(=O)(=O)Cc2cccc(Cl)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CARM1 Q86X55 3/20 0.43
▸ PRMT6 Q96LA8 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ GLA P06280 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ SLC6A2 P23975 4/20 0.42
▸ SLC6A4 P31645 4/20 0.42
▸ NPY1R P25929 1/20 0.38
▸ NPY5R Q15761 1/20 0.38
▸ SLC6A3 Q01959 2/20 0.38
▸ CCR5 P51681 1/20 0.38
▸ HTR1A P08908 2/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ HTR6 P50406 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30270456 1.00 CARM1 (0.43) CARM1PRMT6KDM4EALDH1A1GLA
SCHEMBL26213120 0.89 PRMT6 (0.43) CARM1PRMT6L3MBTL1SLC6A2SLC6A4
SCHEMBL30270433 0.89 PRMT6 (0.43) CARM1PRMT6L3MBTL1SLC6A2SLC6A4
SCHEMBL26213111 0.89 L3MBTL1 (0.42) CARM1PRMT6ALDH1A1GAAL3MBTL1
SCHEMBL26213169 0.83 CYP3A4 (0.43) CARM1PRMT6ALDH1A1HTTL3MBTL1
SCHEMBL26213116 0.82 KDM1A (0.43) CARM1PRMT6ALDH1A1SLC6A2SLC6A4
SCHEMBL26213109 0.80 KDM1A (0.41) CARM1PRMT6SLC6A2SLC6A4KDM1A
SCHEMBL26213059 0.79 KMT2A (0.49) L3MBTL1HTR1AHTR7KDM1A
SCHEMBL26213680 0.78 PRMT6 (0.50) CARM1PRMT6ALDH1A1GAAMAPT
SCHEMBL26213056 0.76 KDM1A (0.53) ALDH1A1HTR1AHTR7KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 — — US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 — — US disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 CARM1 2207/4885PRMT6 1779/4885KDM4E 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback